India: India's Biosimilar Guidance to Come Into Effect in August
Posted 11 July 2012 | By
India's Central Drugs Standard Control Organization (CDSCO) published the final biosimilar guidance setting forth the regulatory requirements for marketing authorization for such products on 4 July 2012.
The guidance covers "similar biologics that contain well-characterized proteins" and permits the use of a reference product not authorized in India, as long as the product has been approved and marketed for at least four years. A post-marketing Risk Management Plan is required because "similar biologics are authorized based on a reduced preclinical and clinical data package."
The guidance goes into effect on August 15, 2012.
CDSCO - Guidelines on Similar Biologics: Regulatory Requirements for marketing Authorization in India
Read all Breaking News from RegLinks